POTELIGEO will be the first biologic agent targeting CCR4 to be available for patients in Europe. Kyowa Hakko Kirin Co., Ltd., (Kyowa Kirin) announces today that it has received a European Commission decision granting a marketing authorisation to POTELIGEO® ...
Alma Announces Launch of PICO CLEAR, a Superior Ultra-Short Picosecond Technology at 5CC in Barcelona, Marking a New Era in Dermatology NUREMBERG, Germany, August 31, 2018 Alma, one of the top five global leaders of energy based medical and aesthetic solutions, today ...